抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识

2019-09-30 中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会 中国实用儿科杂志.2019,34(9):721-728.

中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会邀请儿童耳鼻咽喉、儿童呼吸、变态反应领域的临床专家,共同制定《抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识》,根据婴幼儿生理及AR发病特点,参考国内外循证医学证据,并结合中国专家多年临床经验,重点阐释OA用于婴幼儿AR的治疗方案、安全性、疗效、依从性、剂型和使用方法。本共识将填补国内婴幼儿AR 诊治管理共识的空白,为广大临床医生提供规范化的用药依据。

中文标题:

抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识

发布日期:

2019-09-30

简要介绍:

中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会邀请儿童耳鼻咽喉、儿童呼吸、变态反应领域的临床专家,共同制定《抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识》,根据婴幼儿生理及AR发病特点,参考国内外循证医学证据,并结合中国专家多年临床经验,重点阐释OA用于婴幼儿AR的治疗方案、安全性、疗效、依从性、剂型和使用方法。本共识将填补国内婴幼儿AR 诊治管理共识的空白,为广大临床医生提供规范化的用药依据。

 

拓展指南:过敏性鼻炎相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=0df441c001808577, title=抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识, enTitle=, guiderFrom=中国实用儿科杂志.2019,34(9):721-728., authorId=null, author=, summary=中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会邀请儿童耳鼻咽喉、儿童呼吸、变态反应领域的临床专家,共同制定《抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识》,根据婴幼儿生理及AR发病特点,参考国内外循证医学证据,并结合中国专家多年临床经验,重点阐释OA用于婴幼儿AR的治疗方案、安全性、疗效、依从性、剂型和使用方法。本共识将填补国内婴幼儿AR 诊治管理共识的空白,为广大临床医生提供规范化的用药依据。, cover=, journalId=null, articlesId=null, associationId=1187, associationName=中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会, associationIntro=中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会, copyright=0, guiderPublishedTime=Mon Sep 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会邀请儿童耳鼻咽喉、儿童呼吸、变态反应领域的临床专家,共同制定《抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识》,根据婴幼儿生理及AR发病特点,参考国内外循证医学证据,并结合中国专家多年临床经验,重点阐释OA用于婴幼儿AR的治疗方案、安全性、疗效、依从性、剂型和使用方法。本共识将填补国内婴幼儿AR 诊治管理共识的空白,为广大临床医生提供规范化的用药依据。 </P> <P> </P>拓展指南:<strong>与<font color=red>过敏性鼻炎</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=296501c001e280e4" title="儿童过敏性鼻炎诊疗—临床实践指南" target=_blank>儿童过敏性鼻炎诊疗—临床实践指南</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=76d991c0016102e4" title="中国过敏性鼻炎诊治指南(英文版)" target=_blank>中国过敏性鼻炎诊治指南(英文版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=21c3a1c00152257d" title="2017 AAAAI/ACAAI/JCAAI循证指南:季节性过敏性鼻炎的治疗(更新版)" target=_blank>2017 AAAAI/ACAAI/JCAAI循证指南:季节性过敏性鼻炎的治疗(更新版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8cbc61c001a29ec6" title="2017 EAACI意见书:非过敏性鼻炎" target=_blank>2017 EAACI意见书:非过敏性鼻炎</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ab8491c00136ead0" title="2017 JSA指南:过敏性鼻炎" target=_blank>2017 JSA指南:过敏性鼻炎</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E8%BF%87%E6%95%8F%E6%80%A7%E9%BC%BB%E7%82%8E" target=_blank>有关过敏性鼻炎更多指南</a></ul>, tagList=[TagDto(tagId=58017, tagName=抗组胺药), TagDto(tagId=96039, tagName=婴幼儿过敏性鼻炎)], categoryList=[CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6974, appHits=549, showAppHits=27, pcHits=4332, showPcHits=3165, likes=59, shares=35, comments=4, approvalStatus=1, publishedTime=Sun Oct 27 02:06:54 CST 2019, publishedTimeString=2019-09-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Oct 27 02:06:54 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 00:26:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识)])
抗组胺药治疗婴幼儿过敏性鼻炎的临床应用专家共识
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2161328, encodeId=a23321613283a, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436e8859610, createdName=ms5000001725858949, createdTime=Sat Oct 07 12:40:43 CST 2023, time=2023-10-07, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=962941, encodeId=3a0a962941c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210505/633c6f14bd8f4c6cafcae40cfc8c1a3f/0ced4bbbfabf4bbfa6a0ef0373d45a5f.jpg, createdBy=4cc15492906, createdName=huiyan, createdTime=Wed May 05 23:19:19 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917836, encodeId=920591e8360c, content=感谢!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27245137967, createdName=1466d939m82暂无昵称, createdTime=Mon Jan 18 19:56:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901366, encodeId=50cf90136681, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Nov 23 09:57:50 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2023-10-07 ms5000001725858949 来自广西

    继续学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2161328, encodeId=a23321613283a, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436e8859610, createdName=ms5000001725858949, createdTime=Sat Oct 07 12:40:43 CST 2023, time=2023-10-07, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=962941, encodeId=3a0a962941c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210505/633c6f14bd8f4c6cafcae40cfc8c1a3f/0ced4bbbfabf4bbfa6a0ef0373d45a5f.jpg, createdBy=4cc15492906, createdName=huiyan, createdTime=Wed May 05 23:19:19 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917836, encodeId=920591e8360c, content=感谢!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27245137967, createdName=1466d939m82暂无昵称, createdTime=Mon Jan 18 19:56:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901366, encodeId=50cf90136681, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Nov 23 09:57:50 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2021-05-05 huiyan

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2161328, encodeId=a23321613283a, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436e8859610, createdName=ms5000001725858949, createdTime=Sat Oct 07 12:40:43 CST 2023, time=2023-10-07, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=962941, encodeId=3a0a962941c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210505/633c6f14bd8f4c6cafcae40cfc8c1a3f/0ced4bbbfabf4bbfa6a0ef0373d45a5f.jpg, createdBy=4cc15492906, createdName=huiyan, createdTime=Wed May 05 23:19:19 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917836, encodeId=920591e8360c, content=感谢!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27245137967, createdName=1466d939m82暂无昵称, createdTime=Mon Jan 18 19:56:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901366, encodeId=50cf90136681, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Nov 23 09:57:50 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2021-01-18 1466d939m82暂无昵称

    感谢!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2161328, encodeId=a23321613283a, content=继续学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=436e8859610, createdName=ms5000001725858949, createdTime=Sat Oct 07 12:40:43 CST 2023, time=2023-10-07, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=962941, encodeId=3a0a962941c1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210505/633c6f14bd8f4c6cafcae40cfc8c1a3f/0ced4bbbfabf4bbfa6a0ef0373d45a5f.jpg, createdBy=4cc15492906, createdName=huiyan, createdTime=Wed May 05 23:19:19 CST 2021, time=2021-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917836, encodeId=920591e8360c, content=感谢!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27245137967, createdName=1466d939m82暂无昵称, createdTime=Mon Jan 18 19:56:55 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901366, encodeId=50cf90136681, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be4f5437570, createdName=ms5000001146316601, createdTime=Mon Nov 23 09:57:50 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2020-11-23 ms5000001146316601

    不错

    0